Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229456415> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W4229456415 endingPage "1242" @default.
- W4229456415 startingPage "1235" @default.
- W4229456415 abstract "Chronic kidney disease (CKD) is associated with bone and mineral disturbances in the form of renal osteodystrophy. The American College of Rheumatology Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis 2017 recommend against treatment with denosumab in adult patients who have received an organ transplant and who are continuing treatment with glucocorticoids due to lack of adequate safety data on infections in adults treated with multiple immunosuppressive agents. Therefore, this study was conducted to compare the safety of denosumab in patients with CKD, especially in a group of patients who received immunosuppressive medications, and to assess the rate of infections in such group in comparison to patients with normal renal function. We retrieved all data of patients who are receiving denosumab in our institute through search in the medical record system (Al-Shifa System). We excluded all patients with malignancy and all patients who were prescribed denosumab but did not receive it. During the period from 2006 to 2018, 314 patients were treated with denosumab therapy. Out of 84 patients who were fulfilling the inclusion criteria, 24 (28.5%) patients had normal kidney function and 60 (71.4%) patients had CKD. Forty-three percent of all patients with CKD developed side effects after taking denosumab. In comparison, only 17% of patients with normal kidney function developed side effects. Of patients with CKD and infections, 50% of them had moderate infections and required admission. Out of these patients, 76% were in immunosuppressive medications and 61% of the patients were receiving steroids more than 2.5 mg per day. Using Chi-square test and the nonparametric independent samples Kruskal-Wallis test, there was a significant association between the dose of steroids and the rate of side effects with a significance level of <0.014 and 0.009, respectively. Hypocalcemia was detected in two patients (3.3%), and they had CKD stage V. Denosumab is associated with increased risk of infection in CKD patients on steroids or multiple immuno-suppressive medications. There was no deterioration in renal function while using denosumab. In this regard, close monitoring of this group of patients is essential, as well as medication adjustments." @default.
- W4229456415 created "2022-05-11" @default.
- W4229456415 creator A5011674708 @default.
- W4229456415 creator A5054824194 @default.
- W4229456415 date "2022-05-10" @default.
- W4229456415 modified "2023-09-27" @default.
- W4229456415 title "Safety of denosumab in patients with chronic kidney disease." @default.
- W4229456415 doi "https://doi.org/10.4103/1319-2442.344742" @default.
- W4229456415 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35532692" @default.
- W4229456415 hasPublicationYear "2022" @default.
- W4229456415 type Work @default.
- W4229456415 citedByCount "1" @default.
- W4229456415 countsByYear W42294564152022 @default.
- W4229456415 crossrefType "journal-article" @default.
- W4229456415 hasAuthorship W4229456415A5011674708 @default.
- W4229456415 hasAuthorship W4229456415A5054824194 @default.
- W4229456415 hasConcept C126322002 @default.
- W4229456415 hasConcept C159641895 @default.
- W4229456415 hasConcept C2776286101 @default.
- W4229456415 hasConcept C2776541429 @default.
- W4229456415 hasConcept C2778653478 @default.
- W4229456415 hasConcept C54847362 @default.
- W4229456415 hasConcept C71924100 @default.
- W4229456415 hasConceptScore W4229456415C126322002 @default.
- W4229456415 hasConceptScore W4229456415C159641895 @default.
- W4229456415 hasConceptScore W4229456415C2776286101 @default.
- W4229456415 hasConceptScore W4229456415C2776541429 @default.
- W4229456415 hasConceptScore W4229456415C2778653478 @default.
- W4229456415 hasConceptScore W4229456415C54847362 @default.
- W4229456415 hasConceptScore W4229456415C71924100 @default.
- W4229456415 hasIssue "5" @default.
- W4229456415 hasLocation W42294564151 @default.
- W4229456415 hasOpenAccess W4229456415 @default.
- W4229456415 hasPrimaryLocation W42294564151 @default.
- W4229456415 hasRelatedWork W2112161 @default.
- W4229456415 hasRelatedWork W220526 @default.
- W4229456415 hasRelatedWork W2255904 @default.
- W4229456415 hasRelatedWork W272120 @default.
- W4229456415 hasRelatedWork W2857627 @default.
- W4229456415 hasRelatedWork W3058041 @default.
- W4229456415 hasRelatedWork W3560767 @default.
- W4229456415 hasRelatedWork W4462412 @default.
- W4229456415 hasRelatedWork W4601535 @default.
- W4229456415 hasRelatedWork W98898 @default.
- W4229456415 hasVolume "32" @default.
- W4229456415 isParatext "false" @default.
- W4229456415 isRetracted "false" @default.
- W4229456415 workType "article" @default.